<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17004</article-id><article-id pub-id-type="doi">10.36691/RJA17004</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Possibilities of achieving control of allergic rhinitis in a patient with skin sensitization and continued contact with pets</article-title><trans-title-group xml:lang="ru"><trans-title>Возможность достижения контроля аллергического ринита у пациента с эпидермальной сенсибилизацией и продолжающимся контактом с домашними животными</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7375-1759</contrib-id><contrib-id contrib-id-type="spin">2036-0430</contrib-id><name-alternatives><name xml:lang="en"><surname>Kulichenko</surname><given-names>Darya S.</given-names></name><name xml:lang="ru"><surname>Куличенко</surname><given-names>Дарья Семеновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>darya.mdinaradze@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4164-4094</contrib-id><contrib-id contrib-id-type="spin">7593-0838</contrib-id><name-alternatives><name xml:lang="en"><surname>Pavlova</surname><given-names>Ksenia S.</given-names></name><name xml:lang="ru"><surname>Павлова</surname><given-names>Ксения Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>ksenimedical@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3250-0694</contrib-id><contrib-id contrib-id-type="spin">5698-6436</contrib-id><name-alternatives><name xml:lang="en"><surname>Kurbacheva</surname><given-names>Oksana M.</given-names></name><name xml:lang="ru"><surname>Курбачева</surname><given-names>Оксана Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>kurbacheva@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia</institution></aff><aff><institution xml:lang="ru">Государственный научный центр «Институт иммунологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">ROSUNIMED</institution></aff><aff><institution xml:lang="ru">Российский университет медицины</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-03-05" publication-format="electronic"><day>05</day><month>03</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-04-10" publication-format="electronic"><day>10</day><month>04</month><year>2025</year></pub-date><volume>22</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>107</fpage><lpage>114</lpage><history><date date-type="received" iso-8601-date="2025-02-07"><day>07</day><month>02</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-02-15"><day>15</day><month>02</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, PH “ABV-Press”</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО «ИД «АБВ-пресс»</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">PH “ABV-Press”</copyright-holder><copyright-holder xml:lang="ru">ООО «ИД «АБВ-пресс»</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-04-10"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/17004">https://rusalljournal.ru/raj/article/view/17004</self-uri><abstract xml:lang="en"><p>Skin sensitization is becoming an increasingly common pathology among year-round allergies, and its clinical manifestations vary in patients from the discomfort caused by rhinoconjunctivitis to severe bronchial asthma which can have a huge negative impact on the patient’s quality of life. One of the important recommendations when identifying sensitization to epidermal allergens is complete elimination, but in routine practice this recommendation is not followed in most cases due to the inability to part with the animal. Thus, exposure to the allergen persists and the symptoms continue to bother and progress.</p> <p>The article presents a clinical case of achieving control of allergic rhinitis in a patient with skin sensitization and ongoing contact with pets demonstrating successful experience with the use of a fixed combination of olopatadine and mometasone over a long period of observation.</p></abstract><trans-abstract xml:lang="ru"><p>Эпидермальная сенсибилизация становится все более распространенной патологией среди круглогодичной аллергии, а ее клинические проявления варьируют у пациентов от дискомфорта, вызванного риноконъюнктивитом, до тяжелой бронхиальной астмы, которая может оказать огромное отрицательное влияние на качество жизни пациента. Одной из важных рекомендаций при выявлении сенсибилизации к эпидермальным аллергенам является полная элиминация, однако в рутинной практике эта рекомендация в большинстве случаев не выполняется из-за невозможности расстаться с животным. Тем самым экспозиция аллергена сохраняется, и симптомы продолжают беспокоить и прогрессировать.</p> <p>Представлен клинический случай достижения контроля аллергического ринита у пациента с эпидермальной сенсибилизацией и продолжающимся контактом с домашними животными, продемонстрирован успешный опыт применения фиксированной комбинации олопатадина и мометазона в течение длительного периода наблюдения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>allergic rhinitis</kwd><kwd>cat allergy</kwd><kwd>epidermal allergen</kwd><kwd>intranasal corticosteroid</kwd><kwd>intranasal antihistamine</kwd><kwd>combination nasal medication</kwd><kwd>mometasone</kwd><kwd>olopatadine</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аллергический ринит</kwd><kwd>аллергия на кошек</kwd><kwd>эпидермальный аллерген</kwd><kwd>интраназальный глюкокортикостероид</kwd><kwd>местное антигистаминное средство</kwd><kwd>комбинированный назальный препарат</kwd><kwd>мометазон</kwd><kwd>олопатадин</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This study was supported by Glenmark-Pharma.</funding-statement><funding-statement xml:lang="ru">Исследование и подготовка статьи к публикации проведены при поддержке ООО «Гленмарк Импэкс».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Survey: Almost half of Russian families have pets [electronic resource]. Мoscow, 2019. Available from: https://tass.ru/obschestvo/7168177. Accessed: 19.11.2024.</mixed-citation><mixed-citation xml:lang="ru">Опрос: в почти половине российских семей есть домашние животные [электронный ресурс]. М., 2019. Режим доступа: https://tass.ru/obschestvo/7168177. Дата обращения: 19.11.2024.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Bass E.A. The role of exposure to the main cat allergens (FEL D 1, FEL D 2, FEL D 4) in the sensitizing profile and severity of rhinitis in children. Dis. … candidate of medical sciences. Ekaterinburg, 2019.</mixed-citation><mixed-citation xml:lang="ru">Басс Е.А. Роль экспозиции основных аллергенов кошки (Fel d 1, Fel d 2, Fel d 4) в сенсибилизирующем профиле и тяжести течения аллергического ринита у детей: автореф. дисс. … канд. мед. наук. Екатеринбург, 2019.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. doi: 10.1016/s0140-6736(06)69283-0</mixed-citation><mixed-citation xml:lang="ru">Asher M.I., Montefort S., Björkstén B., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys // Lancet. 2006. Vol. 368, N 9537. P. 733–743. doi: 10.1016/s0140-6736(06)69283-0</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Konradsen JR, Fujisawa T, van Hage M, et al. Allergy to furry animals: new insights, diagnostic approaches, and challenges. J Allergy Clin Immunol. 2015;135(3): 616–625. doi: 10.1016/j.jaci.2014.11.008</mixed-citation><mixed-citation xml:lang="ru">Konradsen J.R., Fujisawa T., van Hage M., et al. Allergy to furry animals: new insights, diagnostic approaches, and challenges // J Allergy Clin Immunol. 2015. Vol. 135, N 3. P. 616–625. doi: 10.1016/j.jaci.2014.11.008</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Allergic rhinitis. Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2024.</mixed-citation><mixed-citation xml:lang="ru">Аллергический ринит. Клинические рекомендации. Российская ассоциация аллергологов и клинических иммунологов; Национальная медицинская ассоциация оториноларингологов; Союз педиатров России. 2024.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Segall N, Prenner B, Lumry W, et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2019;40(5):301–310. doi: 10.2500/aap2019.s19-0003</mixed-citation><mixed-citation xml:lang="ru">Segall N., Prenner B., Lumry W., et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis // Allergy Asthma Proc. 2019. Vol. 40, N 5. P. 301–310. doi: 10.2500/aap2019.s19-0003</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. doi: 10.1016/j.jaci.2019.12.001</mixed-citation><mixed-citation xml:lang="ru">Bousquet J., Schünemann H.J., Togias A., et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence // J Allergy Clin Immunol. 2020. Vol. 145, N 1. P. 70–80.e3. doi: 10.1016/j.jaci.2019.12.001</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Gross GN, Berman G, Amar NJ, et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019;122(6):630–638.e3. doi: 10.1016/j.anai.2019.03.017</mixed-citation><mixed-citation xml:lang="ru">Gross G.N., Berman G., Amar N.J., et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis // Ann Allergy Asthma Immunol. 2019. Vol. 122, N 6. P. 630–638.e3. doi: 10.1016/j.anai.2019.03.017</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Hampel FC, Pedinoff AJ, Jacobs RL, et al. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40(4):261–272. doi: 10.2500/aap2019.s19-0002</mixed-citation><mixed-citation xml:lang="ru">Hampel F.C., Pedinoff A.J., Jacobs R.L., et al. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis // Allergy Asthma Proc. 2019. Vol. 40, N 4. P. 261–272. doi: 10.2500/aap2019.s19-0002</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal clinically important Difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682–688.e6. doi: 10.1016/j.jaip.2016.02.008</mixed-citation><mixed-citation xml:lang="ru">Meltzer E.O., Wallace D., Dykewicz M., Shneyer L. Minimal clinically important difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? // J Allergy Clin Immunol Pract. 2016. Vol. 4, N 4. P. 682–688.e6. doi: 10.1016/j.jaip.2016.02.008</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. doi: 10.1111/j.1365-2222.1991.tb02478</mixed-citation><mixed-citation xml:lang="ru">Juniper E.F., Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis // Clin Exp Allergy. 1991. Vol. 21, N 1. P. 77–83. doi: 10.1111/j.1365-2222.1991.tb02478.x</mixed-citation></citation-alternatives></ref></ref-list></back></article>
